RTL1000

recombinant T cell receptor ligand · Artielle ImmunoTherapeutics

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for RTL1000, covering 2009-02-20 to 2009-02-20. Get the full timeline:

Most recent: Clinical Trial Update: Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis [Phase 1]